Gastrointestinal Hemorrhage Clinical Trial
Official title:
The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Continuing or Discontinuing on Aspirin: a Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial
The risk of bleeding after polypectomy of large colorectal polyps in patients taking aspirin is uncertain. This is a randomized, multi-center, placebo-controlled, double-blind study to compare the risk of significant bleeding after endoscopic polypectomy of large (>=10mm) colorectal polyps in patients continuing or discontinuing on daily acetylsalicylic acid (ASA) use. Eligible patients will be randomly assigned in a 1:1 ratio to a group taking 75mg daily ASA or placebo 7 days before and 14 days following polypectomy. The primary endpoint of the study is bleeding within 30 days from colorectal polypectomy. The secondary endpoints are composite cardiovascular events occurring between the date of randomization and 30 days after polypectomy.
Patients chronically taking aspirin (in prophylaxis doses 75-325 mg), with a diagnosis of colorectal polyps ≥ 10 mm in diameter will be enrolled on a routine polypectomy under hospitalization. Meeting the inclusion criteria, after informed consent and a cardiologist consent the patient will receive aspirin/placebo, and The Patient Diary to fill (Visit 1). The patient will be admitted to the Study Center in 6-7 days taking on the aspirin/placebo and prepared for the study (Visit 2). Patient will be under the care of a physician after polypectomy by a minimum of 6 hours. 14 days after polypectomy will be the first control visit, during which the physician will take back patient diary and pack treatment (Visit 3). 30 days after polypectomy will be the second control visit by phone (Visit 4). Patients will be monitored by looking at the end points. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02903017 -
Local Administration of Tranexamic Acid in Upper Gastrointestinal Hemorrhage
|
Phase 4 | |
Recruiting |
NCT02514304 -
Study of the Risk Factors and Outcomes After Gastrointestinal Bleeding
|
||
Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
Completed |
NCT01477320 -
Enteral Nutrition as Stress Ulcer Prophylaxis in Critically Ill Patients.
|
N/A | |
Completed |
NCT02105532 -
Transfusion in Gastrointestinal Bleeding
|
Phase 2/Phase 3 | |
Recruiting |
NCT05226221 -
Gastrointestinal Emergency Surgery: Evaluation of Morbidity and Mortality
|
||
Active, not recruiting |
NCT02874326 -
Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber
|
Phase 2 | |
Completed |
NCT02928939 -
Therapeutic Conflicts and Multimorbidity
|
||
Withdrawn |
NCT01215058 -
Gastroprotective Agent Compliance in Patients at Risk Suffering From a Gastrointestinal(GI) Ulcer
|
N/A | |
Completed |
NCT01029626 -
Glasgow-Blatschford Score Validation in Digestive Hemorrhage
|
N/A | |
Completed |
NCT00251979 -
A Study to Prevent Rebleeding After Initial Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer
|
Phase 3 | |
Completed |
NCT02991612 -
Rifaximin in Patients With Gastroesophageal Variceal Bleeding
|
N/A | |
Recruiting |
NCT02964195 -
Efficacy of Rifaximin in Treatment of Cirrhotic Gastroesophageal Variceal Bleeding
|
N/A | |
Completed |
NCT02965209 -
European Novel Motorized Spiral Endoscopy Trial
|
N/A | |
Terminated |
NCT02609100 -
Video Capsule Endoscopy Versus Colonoscopy in Patients With Melena and Negative Upper Endoscopy
|
N/A | |
Completed |
NCT01872286 -
Comparison of the Frequency-altering AKE-1 Capsule and Pillcam SB2
|
N/A | |
Completed |
NCT02349490 -
Seraseal for Endoscopic Hemostasis
|
Phase 4 | |
Withdrawn |
NCT01005147 -
Effect of Tranexamic Acid in Upper Gastrointestinal Bleeding
|
N/A | |
Completed |
NCT00570973 -
Band Ligation Versus Transjugular Intrahepatic Portosystemic Stent Shunt (TIPS) in Cirrhotics With Recurrent Variceal Bleeding Non Responding to Medical Therapy
|
Phase 4 | |
Completed |
NCT00450164 -
Secondary Prophylaxis After Variceal Bleeding in Non-Responders
|
Phase 4 |